Viking Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics (NASDAQ:VKTX) reported Q1 earnings with losses of $(0.26) per share, surpassing the analyst consensus estimate of $(0.28) by 7.14%. This represents a 4% increase in losses compared to $(0.25) per share from the same period last year.
April 24, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics reported a smaller-than-expected loss per share for Q1, indicating a potential positive outlook despite an increase in losses year-over-year.
Beating earnings estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. However, the increase in losses year-over-year might temper some of the optimism.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100